CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
LY2216684 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01266590
NCT01266590Phase 1Completed

Effect of LY2216684 on the Pharmacokinetics of Digoxin in Healthy Subjects

Eli Lilly and Company·interventional·Posted Dec 24, 2010·Updated Oct 22, 2018

In Brief

A Phase 1 clinical trial evaluating LY2216684 and Digoxin for Major Depressive Disorder. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with LY2216684. Information about any side effects that may occur will also be collected.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedDec 24, 2010
Enrollment StartDec 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.5 years ago

Interventions

LY2216684drug

Administered orally

Digoxindrug

Administered orally